7,815 results match your criteria Thyroid Medullary Carcinoma


Increased RET activity coupled with a reduction in the gene dosage causes intestinal aganglionosis in mice.

eNeuro 2021 May 6. Epub 2021 May 6.

Division for Neural Differentiation and Regeneration, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan

Mutations of the gene encoding the tyrosine kinase causes Hirschsprung disease (HSCR) and medullary thyroid carcinoma (MTC). Current consensus holds that HSCR and MTC are induced by inactivating and activating RET mutations, respectively. However, it remains unknown whether activating mutations in the gene have adverse effects on ENS development in vivo. Read More

View Article and Full-Text PDF

Invited Commentary: "Familial Non-Medullary Thyroid Carcinoma in Pediatric Age: Our Surgical Experience."

World J Surg 2021 May 6. Epub 2021 May 6.

Department of Surgery, Duke University, Box 3815, Durham, NC, 27710, USA.

View Article and Full-Text PDF

Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).

Cancers (Basel) 2021 Apr 30;13(9). Epub 2021 Apr 30.

Unit of Medical Genetics, Department of Medical and Surgical Sciences; University of Bologna, 40138 Bologna, Italy.

Non-medullary thyroid carcinoma (NMTC) is the most frequent endocrine tumor and originates from the follicular epithelial cells of the thyroid. Familial NMTC (FNMTC) has been defined in pedigrees where two or more first-degree relatives of the patient present the disease in absence of other predisposing environmental factors. Compared to sporadic cases, FNMTCs are often multifocal, recurring more frequently and showing an early age at onset with a worse outcome. Read More

View Article and Full-Text PDF

Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.

Croat Med J 2021 Apr;62(2):110-119

Barbara Perić, Department of Surgical Oncology, Institute of Oncology Ljubljana, Zaloška 2, 1000 Ljubljana, Slovenia,

Aim: To determine the frequency and type of RET mutation in Slovenian medullary thyroid cancer (MTC) patients and estimate the crude annual incidence of MTC in Slovenia.

Methods: This referral-center retrospective analysis involved 186 MTC patients diagnosed between 1995 and 2015 and their relatives who underwent genetic counseling and testing. The crude incidence rate of MTC was estimated with the joinpoint regression analysis. Read More

View Article and Full-Text PDF

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?

Front Endocrinol (Lausanne) 2021 14;12:667784. Epub 2021 Apr 14.

Endocrinology Unit, Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.

Medullary thyroid carcinoma is a rare neuroendocrine neoplasm that originates from thyroid C cells. Surgery, with complete resection of the tumor, is the only curative approach. However, in most cases, the tumor recurs at locoregional or metastatic level. Read More

View Article and Full-Text PDF

MicroRNAs in Medullary Thyroid Carcinoma: A State of the Art Review of the Regulatory Mechanisms and Future Perspectives.

Cells 2021 Apr 20;10(4). Epub 2021 Apr 20.

Pathology Unit, Department of Medicine, University of Padua, Via Gabelli 61, 35121 Padua, Italy.

Medullary thyroid carcinoma (MTC) is a rare malignant neoplasia with a variable clinical course, with complete remission often difficult to achieve. Genetic alterations lead to fundamental changes not only in hereditary MTC but also in the sporadic form, with close correlations between mutational status and prognosis. In recent years, microRNAs (miRNAs) have become highly relevant as crucial players in MTC etiology. Read More

View Article and Full-Text PDF

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib.

Int J Mol Sci 2021 Apr 20;22(8). Epub 2021 Apr 20.

Department of Biochemistry, Faculty of Science, Charles University, Albertov 6, 128 00 Prague 2, Czech Republic.

A tyrosine kinase inhibitor, vandetanib (Van), is an anticancer drug affecting the signaling of VEGFR, EGFR and RET protooncogenes. Van is primarily used for the treatment of advanced or metastatic medullary thyroid cancer; however, its usage is significantly limited by side effects, particularly cardiotoxicity. One approach to minimize them is the encapsulation or binding of Van in- or onto a suitable carrier, allowing targeted delivery to tumor tissue. Read More

View Article and Full-Text PDF

Occurrence of sporadic medullary thyroid carcinoma in Graves' disease in association with a RET proto-oncogene mutation.

Acta Clin Belg 2021 Apr 29:1-4. Epub 2021 Apr 29.

Unit of Digestive, Endocrine and General Surgery, Department of Surgery, Université Catholique de Louvain, Yvoir, Belgium.

: Graves' disease may be associated with thyroid cancer, particularly differentiated thyroid cancer. Medullary thyroid cancer (MTC) is less common. The occurrence of sporadic MTC in Graves' disease in the presence of a RET proto-oncogene has never been reported. Read More

View Article and Full-Text PDF

Case Report: Next-Generation Sequencing Reveals Tumor Origin in a Female Patient With Brain Metastases.

Front Oncol 2021 12;11:569429. Epub 2021 Apr 12.

Neurosurgery department, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Background: Brain metastasis mainly originates from lung cancer. Napsin A and TTF-1 factors have frequently been detected in lung adenocarcinoma cases. Brain metastasis tumors with napsin A and TTF-1 positive are easily classified as lung adenocarcinoma origin. Read More

View Article and Full-Text PDF

Multimodality Imaging Review of Multiple Endocrine Neoplasia.

AJR Am J Roentgenol 2021 Apr 28:1-12. Epub 2021 Apr 28.

Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT.

The purpose of this article is to review the clinical manifestations, endocrine tumors types, and multimodality diagnostic tools available to physicians involved in the management of patients with multiple endocrine neoplasia (MEN) syndrome, in addition to discussing relevant imaging findings and appropriate imaging follow-up. Thorough knowledge of the spectrum of tumors associated with gene mutations aids in the screening, diagnostic workup, and posttreatment monitoring of patients with MEN-related gene mutations. Read More

View Article and Full-Text PDF

[The Therapy of Malignant Thyroid Disease from ENT-Perspective].

Laryngorhinootologie 2021 Apr 27. Epub 2021 Apr 27.

Klinik für Hals-Nasen-Ohrenheilkunde, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.

Introduction:  Malignant tumours of the thyroid gland show a rising incidence. As in the ENT-department Bad Hersfeld the management of thyroid disorders has been in focus for a longer period, we want to share our experiences in this field.

Material And Methods:  The investigation started in the year of 2014 till July 2020. Read More

View Article and Full-Text PDF

Metastatic leiomyosarcoma of the thyroid: A rare entity.

Malays J Pathol 2021 Apr;43(1):69-73

Universiti Sains Malaysia, School of Medical Sciences, Deparment of Pathology, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia.

Cancer metastasis to the thyroid gland from non-thyroid sites is a rare presentation in clinical practice. The most frequent primary cancers that metastasise to the thyroid are renal cell carcinoma, followed by colorectal, lung and breast. We report a case of a 64-year-old Malay lady who presented with anterior neck swelling 4 years after an initial diagnosis of uterine leiomyosarcoma. Read More

View Article and Full-Text PDF

Metastatic medullary thyroid carcinoma presenting as ectopic Cushing's syndrome.

Endocrinol Diabetes Metab Case Rep 2021 Apr 1;2021. Epub 2021 Apr 1.

Department of Endocrinology, Mater Misericordiae University Hospital, Dublin, Ireland.

Summary: A 41-year-old male presented to the Emergency Department with a 6-month history of back and hip pain. Skeletal survey revealed bilateral pubic rami fractures and MRI of the spine demonstrated multiple thoracic and lumbar fractures. Secondary work up for osteoporosis was undertaken. Read More

View Article and Full-Text PDF

Familial Non-Medullary Thyroid Carcinoma in Pediatric Age: Our Surgical Experience.

World J Surg 2021 Apr 23. Epub 2021 Apr 23.

Pediatric and Adolescent Surgery Division, Department of Pathology Surgery, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.

Background: The purpose of the article was to evaluate the existence of significant clinical, pathological and prognostic differences between familial and sporadic form of pediatric non-medullary thyroid carcinoma, in order to tailor the therapeutic strategy to be adopted for patients with family history.

Methods: We analyzed the records of 76 pediatric patients that underwent surgery for differentiated thyroid cancer from 2014 to 2019 at the Surgical Pathology Department of the University of Pisa, Italy. Among these, 20 (26,3%) had positive family history (familial non-medullary thyroid carcinoma-FNMTC group) while 56 (73. Read More

View Article and Full-Text PDF

Clinical relevance of F-FDG PET/CT in the postoperative follow-up of patients with history of medullary thyroid cancer.

Radiol Oncol 2020 Nov 22;55(1):18-25. Epub 2020 Nov 22.

Center for Nuclear Medicine, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Background: The aim of the study was evaluation of F-fluorodeoxyglucose (F-FDG) positron emission tomography with computed tomography (PET/CT) in the detection of active disease in the patients with suspected recurrence of the medullary thyroid carcinoma (MTC).

Patients And Methods: F-FDG PET/CT investigation was performed in 67 patients, investigated from 2010 to 2019. _ Follow up was performed from 6 to 116 months after surgery (median 16. Read More

View Article and Full-Text PDF
November 2020

Diagnostic Challenges of Medullary Thyroid Carcinoma.

Oncology 2021 Apr 20:1-11. Epub 2021 Apr 20.

Division of Endocrinology, Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.

Background: Medullary thyroid carcinoma (MTC) comprises 1-2% of all thyroid cancers, yet 15% of all thyroid cancer-related deaths. While up to 20% of cases may be predicted due to autosomal dominant germline mutations, 80% of cases are sporadic. However, due to non-specific presenting symptoms and diagnostic imaging, prompt diagnosis and treatment has remained elusive. Read More

View Article and Full-Text PDF

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.

Thyroid 2021 Apr 16. Epub 2021 Apr 16.

Massachusetts General Hospital, 55 Fruit St, Boston, Massachusetts, United States, 02114;

Background: Thyroid cancer is a common malignancy whose detection has increased significantly in past decades. Most of the increased incidence is due to detection of early well-differentiated thyroid cancer, but the incidence of more advanced thyroid cancers has increased as well. Recent methodological advancements have allowed for a deep understanding of the molecular underpinnings of the various types of thyroid cancer. Read More

View Article and Full-Text PDF

Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma.

Clin Chem Lab Med 2021 Apr 16. Epub 2021 Apr 16.

Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Objectives: Serum calcitonin (CT) is pivotal in medullary thyroid cancer (MTC) management. Recently, progastrin releasing peptide (ProGRP) has been proposed as a candidate complementary tumor marker of MTC. As current data are sparse our study was undertaken to evaluate the distribution of ProGRP in patients with MTC and its relationship with the tumor burden. Read More

View Article and Full-Text PDF

Serum miR-375 for Diagnostic and Prognostic Purposes in Medullary Thyroid Carcinoma.

Front Endocrinol (Lausanne) 2021 29;12:647369. Epub 2021 Mar 29.

Endocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.

Purpose: Having previously demonstrated that tissue miR-375 expression in medullary thyroid carcinoma (MTC) tissues is linked to prognosis, the aim of this study was to assess the diagnostic and prognostic value of circulating miR-375 levels in MTC patients.

Methods: A series of 68 patients with MTC was retrospectively retrieved and assessed in terms of their clinicopathological characteristics. MiR-375 levels were measured in all patients' presurgical blood samples. Read More

View Article and Full-Text PDF

Ultrasonic Characteristics of Medullary Thyroid Carcinoma: Differential From Papillary Thyroid Carcinoma and Benign Thyroid Nodule.

Ultrasound Q 2021 Apr 10. Epub 2021 Apr 10.

Ultrasound Department, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Abstract: The aim of this study was to evaluate the differences in ultrasonic features of patients with medullary thyroid carcinoma (MTC), papillary thyroid carcinoma (PTC), and benign thyroid nodules. This study included 53 cases of MTC, 151 cases of PTC, and 200 cases of benign thyroid nodule which were pathologically confirmed. There were no significant differences in sex and thyroid gland involvement among the MTC, PTC, and benign thyroid nodule groups. Read More

View Article and Full-Text PDF

Papillary and Medullary Thyroid Carcinomas Presenting as Collision Tumors: A Case Series of 21 Cases at a Tertiary Care Cancer Center.

Head Neck Pathol 2021 Apr 11. Epub 2021 Apr 11.

Homi Bhabha National Institute, Mumbai, 400012, India.

Collision tumor is the occurrence of two histologically and morphologically distinct tumors within the same organ with no histological admixture. Collision tumors of the thyroid are extremely rare constituting < 1% of all thyroid tumors. Clinical profiles and pathological features of Medullary thyroid carcinoma (MTC) and Papillary thyroid carcinoma (PTC) presenting as Collision tumors of thyroid, diagnosed between 2009 and 2019, at a tertiary care cancer center were retrospectively analyzed. Read More

View Article and Full-Text PDF

Lymph node metastases in pediatric medullary thyroid carcinoma.

Surgery 2021 Apr 7. Epub 2021 Apr 7.

Department of Otolaryngology-Head and Neck Surgery, New York University Grossman School of Medicine, NY. Electronic address:

Background: Unlike medullary thyroid carcinoma in adults, the vast majority of pediatric medullary thyroid carcinoma is hereditary. Pediatric medullary thyroid carcinoma is known to have different genetic alterations driving tumorigenesis, but it is not known if pediatric medullary thyroid carcinoma has different clinicopathologic features. This study aims to identify which pediatric medullary thyroid carcinoma patients might warrant elective neck dissection. Read More

View Article and Full-Text PDF

Ultrasound features of medullary thyroid cancer as predictors of biological behavior.

Cancer Imaging 2021 Apr 9;21(1):33. Epub 2021 Apr 9.

Departments of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, P. R. China.

Background: Medullary thyroid cancer (MTC) has more aggressive behavior and poor prognosis. Ultrasound (US) has facilitated the qualitative diagnosis of thyroid nodules, however, some MTC may be diagnosed as a benign nodule on ultrasound because ultrasound features of malignancy are lacking. The aim of the study was to investigate the association between ultrasound features and biological behavior of MTC. Read More

View Article and Full-Text PDF

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.

Clin Cancer Res 2021 Apr 8. Epub 2021 Apr 8.

Department of Thyroid and Neck Oncology, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy; Tianjin Union Medical Center

Purpose: Medullary thyroid cancer (MTC) accounts for about 2% of all thyroid cancer, but has a relatively poor prognosis compared with differentiated thyroid cancer. Anlotinib is a novel multitarget tyrosine kinase inhibitor targeting VEGFR, PDGFR, FGFR and c-Kit. This multicenter, randomized, double-blind, placebo-controlled phase ⅡB study (ALTER 01031, NCT02586350) was conducted to investigate the efficacy and safety of anlotinib in MTC. Read More

View Article and Full-Text PDF

Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.

Medicine (Baltimore) 2021 Apr;100(14):e25315

Department of Nuclear Medicine.

Background: Programmed cell death ligand 1 (PD-L1), which is highly expressed in a variety of malignant tumors, is closely related to clinicopathological features and prognosis. However, there are few studies on the potential effects of PD-L1 on thyroid carcinoma, the incidence of which has shown an upward trend worldwide. This study aimed to explore the association between PD-L1 expression and clinicopathological features and prognosis of thyroid cancer. Read More

View Article and Full-Text PDF

Synchronous intrathyroidal parathyroid carcinoma and thyroid carcinoma: case report and review of the literature.

BMC Endocr Disord 2021 Apr 7;21(1):60. Epub 2021 Apr 7.

General Surgery Unit, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia, 80138, Naples, Italy.

Background: Parathyroid carcinoma is a rare endocrine malignancy, rarer when synchronous with a non medullary well differentiated thyroid carcinoma. Parathyroid carcinoma accounts of 0.005% of all malignant tumors and it is responsible for less than 1% of primary hyperparathyroidism. Read More

View Article and Full-Text PDF

Management and results of thyroidectomies in pediatric patients with men 2 syndrome.

J Pediatr Surg 2021 Mar 3. Epub 2021 Mar 3.

Department of Pediatric Surgery, Gregorio Marañón University Hospital Máiquez Street N 9, 28007 Madrid, Spain.

Aim Of The Study: To evaluate the outcome of prophylactic thyroidectomies (PT) in patients with MEN 2 syndrome in a tertiary center.

Methods: A retrospective study was designed, including all patients with MEN 2 syndrome who underwent PT between 2000 and 2019. Demographics, gene mutation, postoperative complications and histopathological findings were registered. Read More

View Article and Full-Text PDF

Multiple endocrine neoplasia type 2: A reveiw.

Semin Cancer Biol 2021 Apr 1. Epub 2021 Apr 1.

Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Institute of Clinical Medicine, Faculty of Health Sciences, Copenhagen University, Copenhagen, Denmark. Electronic address:

Multiple endocrine neoplasias are rare hereditary syndromes some of them with malignant potential. Multiple endocrine neoplasia type 2 (MEN 2) is an autosomal dominant hereditary cancer syndrome due to germline variants in the REarranged during Transfection (RET) proto-oncogene. There are two distinct clinical entities: MEN 2A and MEN 2B. Read More

View Article and Full-Text PDF

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.

Int J Mol Sci 2021 Mar 16;22(6). Epub 2021 Mar 16.

Laboratory of Geriatric and Oncologic Neuroendocrinology Research, Istituto Auxologico Italiano, IRCCS, 20095 Cusano Milanino, MI, Italy.

Medullary thyroid carcinoma (MTC) is a tumor deriving from the thyroid C cells. Vandetanib (VAN) and cabozantinib (CAB) are two tyrosine kinase inhibitors targeting REarranged during Transfection (RET) and other kinase receptors and are approved for the treatment of advanced MTC. We aim to compare the in vitro and in vivo anti-tumor activity of VAN and CAB in MTC. Read More

View Article and Full-Text PDF

Correlation between preoperative ultrasonic features of medullary thyroid carcinoma and postoperative recurrence.

Authors:
Qiaodan Zhu Dong Xu

BMC Cancer 2021 Apr 1;21(1):344. Epub 2021 Apr 1.

Wenzhou Medical University, Wenzhou, 325600, Zhejiang Province, China.

Background: To investigate the factors that affect postoperative recurrence in medullary thyroid carcinoma (MTC) patients, including preoperative ultrasonic characteristics and other factors.

Method: A retrospective analysis of 7 MTC patients who underwent the first thyroid surgery from 2009 to 2018 and who had complete follow-up data was conducted. According to the follow-up results, these patients were divided into the recurrence group (17 cases) and non-recurrence group (57 cases). Read More

View Article and Full-Text PDF